Senior Vice President and CAO (Former Interim Principal Financial Officer) · Jazz Pharmaceuticals plc (JAZZ)

Patricia Carr

A named executive officer of Jazz Pharmaceuticals in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,452,210

Salary $429,954Stock awards $761,822

FY2023: $1,401,028

7th of 7 named executive officers at Jazz Pharmaceuticals by FY2024 total.

7 named officers on file for Jazz Pharmaceuticals, FY2024

Patricia Carr’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • JAZZ’s disclosed peer group of 13 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Jazz Pharmaceuticals’s whole pay program stands against its peers

  • Jazz Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on JAZZ→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 6, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Patricia Carr’s full pay file as a PDF — free

More than this page: up to 10 years of Patricia’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Patricia Carr compensation by year

Jazz Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Jazz Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$402,181$429,954
Bonus$0$0
Stock awards$767,623$761,822
Option awards$0$0
Non-equity incentive$194,868$220,713
Pension and deferred compensation$0$0
All other$36,356$39,722
Total$1,401,028$1,452,210

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Jazz Pharmaceuticals plc DEF 14A filed June 6, 2025, accession 0001232524-25-000043, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Jazz Pharmaceuticals plc filed document, accession 0001232524-25-000043. Every figure is read from that document and cited to the page and table it appears in. Filed June 6, 2025.

$1.4M
$1.5M
FY23
FY24
SalaryNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU5,974$735,698—
RSU2,987$367,849—
PSU2,523$310,707—
RSU1,892$233,000—
RSU1,641$202,089—
RSU1,244$153,199—
RSU473$58,250—

Per the Outstanding Equity Awards at Fiscal Year-End table in Jazz Pharmaceuticals plc's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

18 Form 4 lines since the FY2024 proxy (filed June 6, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-04Exercise or conversion derivative—1,250$0.003,000
2026-11-04Sale—163$231.276,512
2026-11-04Exercise or conversion—1,250$140.037,925
2026-11-04Sale—1,250$231.376,675
2026-03-09Sale—1,287$182.946,512
2026-03-05Tax withholding—1,436$186.777,799
2026-02-27Sale—1,117$190.919,235
2026-02-26Grant or award—2,223$0.0011,605

The 8 most recent of 18 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments Jazz Pharmaceuticals discloses, by trigger · FY2024
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control, no termination$0$1,797,250$0$1,797,250
Change in control and involuntary termination$1,203,553$1,797,250$2,962$3,003,765
Disability$0$812,297$0$812,297
Death$0$1,428,123$0$1,428,123
Retirement$0$0—$0

Per the Potential Payments Upon Termination or Change in Control table in Jazz Pharmaceuticals plc's FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.

Jazz Pharmaceuticals’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Bruce CozaddChairperson and CEO$15,527,464
Renée GaláPresident and COO$6,628,888
Robert IannoneExecutive Vice President, Global Head of Research and Development and Chief Medical Officer$5,689,377
Philip JohnsonExecutive Vice President and CFO$5,243,445
Samantha PearceExecutive Vice President, CCO$4,464,254
Neena PatilExecutive Vice President and Chief Legal Officer$4,309,074
Patricia Carr · this pageSenior Vice President and CAO (Former Interim Principal Financial Officer)$1,452,210

The full Jazz Pharmaceuticals compensation record

free company brief

This page is one person within Jazz Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Jazz Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Jazz Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Patricia Carr's compensation dossier · One-time report. No refunds.